Price Action Alert: TherapeuticsMD Inc Hit Yearly Low

Price Action Alert: TherapeuticsMD Inc Hit Yearly Low

The stock of TherapeuticsMD Inc (NYSEMKT:TXMD) hit a new 52-week low and has $4.81 target or 6.00% below today’s $5.12 share price. The 6 months bearish chart indicates high risk for the $967.48 million company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $4.81 price target is reached, the company will be worth $58.05 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 7.25% or $0.4 during the last trading session, hitting $5.12. About 2.83 million shares traded hands or 52.15% up from the average. TherapeuticsMD Inc (NYSEMKT:TXMD) has declined 13.75% since March 31, 2016 and is downtrending. It has underperformed by 16.27% the S&P500.

TherapeuticsMD Inc (NYSEMKT:TXMD) Ratings Coverage

Out of 3 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. TherapeuticsMD has been the topic of 4 analyst reports since September 21, 2015 according to StockzIntelligence Inc. Stifel Nicolaus maintained TherapeuticsMD Inc (NYSEMKT:TXMD) on Tuesday, December 8 with “Buy” rating. Jefferies maintained TherapeuticsMD Inc (NYSEMKT:TXMD) rating on Tuesday, December 8. Jefferies has “Buy” rating and $18.0 price target. Jefferies maintained TherapeuticsMD Inc (NYSEMKT:TXMD) on Monday, September 21 with “Buy” rating.

According to Zacks Investment Research, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida.”

Insitutional Activity: The institutional sentiment decreased to 1.25 in Q2 2016. Its down 0.78, from 2.03 in 2016Q1. The ratio worsened, as 19 funds sold all TherapeuticsMD Inc shares owned while 29 reduced positions. 13 funds bought stakes while 47 increased positions. They now own 158.58 million shares or 4.25% more from 152.12 million shares in 2016Q1.
Morgens Waterfall Vintiadis & Inc last reported 1.41% of its portfolio in the stock. Hightower Advsr Llc owns 20,000 shares or 0% of their US portfolio. California State Teachers Retirement has 0.01% invested in the company for 314,724 shares. Moreover, Manufacturers Life The has 0% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 103,248 shares. Rhumbline Advisers has 157,154 shares for 0% of their US portfolio. Vanguard Gru Incorporated Inc holds 0% or 8.75M shares in its portfolio. Nationwide Fund Advsrs last reported 0% of its portfolio in the stock. Huntington Financial Bank has 3,000 shares for 0% of their US portfolio. Ameritas Invest Prtnrs holds 0.01% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD) for 11,413 shares. Goldman Sachs Grp last reported 0% of its portfolio in the stock. State Bank Of Montreal Can last reported 73,000 shares in the company. Paradigm Asset Mngmt reported 12,750 shares or 0% of all its holdings. Commonwealth Equity has 0% invested in the company for 17,100 shares. Teachers Advsrs, a New York-based fund reported 237,923 shares. Pub Employees Retirement Association Of Colorado, a Colorado-based fund reported 40,500 shares.

TXMD Company Profile

TherapeuticsMD, Inc., incorporated on July 20, 2010, is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. The Firm is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The Company’s drug candidates used in its clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. The Company’s drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination. The Firm makes and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment